PUBLISHER: GlobalData | PRODUCT CODE: 2094948
PUBLISHER: GlobalData | PRODUCT CODE: 2094948
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast
Hepatocellular carcinoma (HCC) arises from the hepatocyte cells in the liver and is the most common primary liver cancer, accounting for approximately 90% of all primary cancers of the liver (Asafo-Agyei and Samant, 2023). HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide (Singal, Kanwal and Llovet, 2023). Major risk factors for HCC include infection with the hepatitis B virus (HBV), infection with the hepatitis C virus (HCV), and high alcohol consumption (McGlynn, Petrick and El-Serag, 2021). HCC occurs in approximately 85% of patients with cirrhosis of the liver, a crucial element in the development of HCC. HCC is nearly three times as common in men than women, possibly due to higher infection with HBV and HCV, higher alcohol and cigarette consumption on average, or higher iron levels in men (Nevola et al., 2023).
Scope
- The model includes a 10-year epidemiological forecast for the diagnosed incident cases, five-year diagnosed prevalent cases, and all-time diagnosed prevalent cases of HCC.
- Diagnosed incident cases are segmented by age (starting from 18 up to 85 years and older by 5-year age groups) and sex. Additionally, the diagnosed incident cases of HCC are segmented by BCLC stage, Child Pugh stage, HKLC stage, HCC risk factors (hepatitis B, hepatitis C, MASLD/MASH, alcohol), cirrhotic vs non-cirrhotic, and biomarkers. Additionally, the model incudes all-time diagnosed prevalent cases of HCC segmented by BCLC Stage.
Reasons to Buy
The HCC Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global HCC markets.
- Quantify patient populations in the global HCC markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCC therapeutics in each of the markets covered.
- Understand the magnitude of the HCC population by age, sex, BCLC stage, Child-Pugh stage, HKLC stage, risk factors, cirrhotic and non-cirrhotic HCC, and biomarkers.
Table of Contents
Table of Contents
1. Preface
- 1.1. Contents
2. Executive Summary
3. Disease Overview
- 3.1. Background
- 3.2. Risk Factors and Comorbidities
4. Epidemiological Forecast
- 4.1. Diagnosed Incident Cases of HCC, N, All Ages, Men and Women, 2024-34
- 4.2. Age-Specific Trends in Diagnosed Incident Cases of HCC, N, Men and Women, 2024
- 4.3. Sex-Specific Diagnosed Incident Cases of HCC, N, All Ages, 2024
- 4.4. Sex-Specific Diagnosed Incident Cases of HCC, N, All Ages, 2024
- 4.5. Trends of Diagnosed Incident Cases of HCC, N, All Ages, 2014-34
- 4.6. Diagnosed Incident Cases of HCC by Barcelona Clinic Liver Cancer Stage, N, All Ages, 2024
- 4.7. Diagnosed Incident Cases of HCC by Child Pugh Stage, N, All Ages, 2024
- 4.8. Diagnosed Incident Cases of HCC by Hong Kong Liver Cancer Stage, N, All Ages, 2024
- 4.9. Diagnosed Incident Cases of HCC by Risk Factor, N, All Ages, 2024
- 4.10. Diagnosed Incident Cases of HCC by Cirrhotic Versus Non-Cirrhotic, N, All Ages, 2024
- 4.11. Diagnosed Incident Cases of HCC by Biomarker, N, All Ages, 2024
- 4.12. Five-Year Diagnosed Prevalent Cases of HCC, N, All Ages, Men and Women, 2024-34
- 4.13. All-time Diagnosed Prevalent Cases of HCC by Barcelona Clinic Liver Cancer Stage, N, All Ages, 2024
5. Sources and Methodology
- 5.1. Sources and Methodology for HCC Incidence
- 5.2. Diagnosed Incident Cases of HCC
- 5.3. Diagnosed Incident Cases of HCC by Barcelona Clinic Liver Cancer Stage
- 5.4. Diagnosed Incident Cases of HCC by Child Pugh Stage
- 5.5. Diagnosed Incident Cases of HCC by Hong Kong Liver Cancer Stage
- 5.6. Diagnosed Incident Cases of HCC by Japan Integrated Staging Stage (Japan only)
- 5.7. Diagnosed Incident Cases of HCC by China Liver Cancer Stage (China only)
- 5.8. Diagnosed Incident Cases of HCC by Risk Factors
- 5.9. Diagnosed Incident Cases of HCC by Cirrhotic Versus Non-Cirrhotic
- 5.10. Diagnosed Incident Cases of HCC by Biomarkers
- 5.11. Five-Year Diagnosed Prevalent Cases of HCC
- 5.12. All-Time Diagnosed Prevalent Cases of HCC by Barcelona Clinic Liver Cancer Stage
6. Discussion
- 6.1. Epidemiological Forecast Insight
- 6.2. Strengths and Limitations
7. Appendix
- 7.1. Bibliography
- 7.2. About the Authors
8. Contact Us
List of Table
Diagnosed Incident Cases of HCC by Hong Kong Liver Cancer Stage, N, All Ages, 2024
Diagnosed Incident Cases of HCC by Biomarker, N, All Ages, 2024
List of Figure
Diagnosed Incident Cases of HCC, N, All Ages, Men and Women, 2024-34
Age-Specific Trends in Diagnosed Incident Cases of HCC, N, Men and Women, 2024
Sex-Specific Diagnosed Incident Cases of HCC, N, All Ages, 2024
Sex-Specific Diagnosed Incident Cases of HCC, N, All Ages, 2024
Trends of Diagnosed Incident Cases of HCC, N, All Ages, 2014-34
Diagnosed Incident Cases of HCC by Barcelona Clinic Liver Cancer Stage, N, All Ages, 2024
Diagnosed Incident Cases of HCC by Child Pugh Stage, N, All Ages, 2024
Diagnosed Incident Cases of HCC by Risk Factor, N, All Ages, 2024
Diagnosed Incident Cases of HCC by Cirrhotic Versus Non-Cirrhotic, N, All Ages, 2024
Five-Year Diagnosed Prevalent Cases of HCC, N, All Ages, Men and Women, 2024-34
All-time Diagnosed Prevalent Cases of HCC by Barcelona Clinic Liver Cancer Stage, N, All Ages, 2024
